Cagrilintide
Next-gen appetite control via amylin pathway
Weight Losssubcutaneousany
Overview
Long-acting amylin analogue that reduces appetite and slows gastric emptying. Being developed in combination with semaglutide (CagriSema) for enhanced weight loss.
Dosing
- Typical Dosage
- 2.4 mg
- Frequency
- Weekly
- Cycle Duration
- Ongoing
- Administration
- subcutaneous
Available Vial Sizes
5mg10mg20mg
Often combined with semaglutide. Titrate slowly to minimise GI side effects.
Comprehensive Information
AI-GeneratedGenerating comprehensive analysis...
This may take a moment
Mechanism of Action
Key Benefits
Optimal Timing
Potential Side Effects
Stacking Suggestions
Practical Tips
Could not load AI-generated information
Track Your Cagrilintide Protocol
Join UpgradeYourself to track your peptide protocols, log injections with our interactive body map, and receive AI-powered insights tailored to your health goals.
Free forever planNo credit card required100+ peptides tracked